CD20-positive B-cell malignancies treated with rituximab in Nagoya University Hospital
| . | No. of patients . | Disease status at rituximab therapy . | Response, RD/PD . | Resampling of tumor tissue . | CD20 expression, +/±/− . | |
|---|---|---|---|---|---|---|
| 1st . | RD/PD . | |||||
| DLBCL | 51 | 45 | 6 | 13 | 6 | 3/1/2 |
| FL | 43 | 26 | 17 | 13 | 7 | 5/0/2 |
| Nodal marginal zone BCL or MALT | 8 | 6 | 2 | 2 | 2 | 2/0/0 |
| Burkitt or Burkitt-like | 5 | 5 | 0 | 4 | 2 | 2/0/0 |
| Mediastinal large B-cell | 4 | 2 | 2 | 1 | 0 | 0 |
| Intravascular large B-cell | 4 | 4 | 0 | 2 | 1 | 1/0/0 |
| Mantle cell | 4 | 3 | 1 | 1 | 1 | 1/0/0 |
| Lymphoplasmacytic | 3 | 3 | 0 | 0 | 0 | 0 |
| CLL/SLL | 2 | 1 | 1 | 0 | 0 | 0 |
| Total cases | 124 | 96 | 28 | 36 | 19 | 14/1/4 |
| Probability (%) | 36/124 (29.0) | 19/36 (52.5) | 5/19 (26.3) | |||
| . | No. of patients . | Disease status at rituximab therapy . | Response, RD/PD . | Resampling of tumor tissue . | CD20 expression, +/±/− . | |
|---|---|---|---|---|---|---|
| 1st . | RD/PD . | |||||
| DLBCL | 51 | 45 | 6 | 13 | 6 | 3/1/2 |
| FL | 43 | 26 | 17 | 13 | 7 | 5/0/2 |
| Nodal marginal zone BCL or MALT | 8 | 6 | 2 | 2 | 2 | 2/0/0 |
| Burkitt or Burkitt-like | 5 | 5 | 0 | 4 | 2 | 2/0/0 |
| Mediastinal large B-cell | 4 | 2 | 2 | 1 | 0 | 0 |
| Intravascular large B-cell | 4 | 4 | 0 | 2 | 1 | 1/0/0 |
| Mantle cell | 4 | 3 | 1 | 1 | 1 | 1/0/0 |
| Lymphoplasmacytic | 3 | 3 | 0 | 0 | 0 | 0 |
| CLL/SLL | 2 | 1 | 1 | 0 | 0 | 0 |
| Total cases | 124 | 96 | 28 | 36 | 19 | 14/1/4 |
| Probability (%) | 36/124 (29.0) | 19/36 (52.5) | 5/19 (26.3) | |||
DLBCL indicates diffuse large B-cell lymphoma; FL, follicular lymphoma; BCL, B-cell lymphoma; MALT, mucosa-associated lymphoid tissue; CLL/SLL, clonic lymphocytic leukemia/small lymphocytic lymphoma; 1st, the first treatment; RD/PD, relapse or progression; and +/±/−; positive/decreased/negative.